SRTD Biotech funding, valuation and investors

SRTD Biotech, headquartered in Jülich, Germany, announced completion of an oversubscribed €31.5 million seed financing on November 9, 2026. Mérieux Equity Partners led through its Mérieux Innovation 2 strategy; NRW.BANK and Boehringer Ingelheim Venture Fund were co-leads. Lilly Ventures, High-Tech Gründerfonds (HTGF), and family office Anobis Asset also participated.

NRW.BANK independently disclosed a €7 million investment through NRW.Venture EU Tech&Scale; this is a component of the €31.5 million round, not another financing. Valuation and each other investor's cheque are undisclosed. The company was established in 2019 around Bernd Hoffmann and Heribert Bohlen's work; Matthias Alder was appointed CEO following the round.

What it does: the seRNA technology combines an antisense sensor for a disease-associated RNA inside a cell with an mRNA expression payload. A blocking mechanism is intended to prevent production of a therapeutic effector until the sensor encounters the relevant intracellular RNA, at which point cellular cleavage enables translation.

The company is separately developing fusogenic lipid nanoparticles (fLNPs) to reach particular organs and help deliver cargo into the cytosol, plus a synthetic-biology/AI design pipeline to select sensors and constructs. Disease-cell specificity and organ delivery are distinct technical challenges: success at one does not prove success at the other.

Illustrative therapeutic development route, NOT a clinical treatment: (1) researchers identify RNA markers that distinguish a diseased cell population from normal tissue; (2) design seRNA sensors and a therapeutic payload, such as a protein inducing programmed cell death; (3) test whether the construct activates in diseased cells while staying silent in controls; (4) optimize LNP formulation and delivery in relevant animal models; (5) conduct biodistribution, repeated-dose, toxicology and manufacturing work needed before a possible IND submission and first-in-human trial.

There is no marketed SRTD medicine, patient price, reimbursed product, clinical revenue or clinical efficacy result disclosed.

Independent scientific baseline: Rastfeld et al., Nature Communications, January 6, 2025, DOI 10.1038/s41467-024-55547-6, studied RNA-dependent target activation and apoptosis in cells and limited early glioblastoma clusters in male mice. This is peer-reviewed *preclinical* evidence, not proof that a systemic drug will safely treat established human tumors.

The paper itself highlights limitations of its U87 mouse tumor model, the need for other models and established tumors, repeated dosing and longer observation, plus delivery barriers including the blood-brain barrier. Its limited experiments should not be generalized to all cancers, fibrosis or autoimmune conditions.

Competitors/alternatives span conventional antibody-drug conjugates and bispecific therapies that rely on surface-accessible targets, LNP-delivered mRNA and siRNA programs that require optimized delivery and RNA selectivity, and emerging RNA-sensor therapies. These are overlapping technology approaches, not proven head-to-head competitors.

The company targets oncology, autoimmune disease and fibrosis and intends to advance candidate drugs through preclinical/IND-enabling work. No candidate's IND clearance, clinical trial or commercial manufacturing has been verified.

Sources: SRTD original Nov 9 release https://srtd-biotech.com/news/ ; investor https://merieux-partners.com/news/merieux-innovation-2-invests-in-srtd-biotech-a-leading-biotechnology-company/ ; NRW.BANK original https://www.nrwbank.de/de/info-und-service/presseinformationen/2026/261109_PI_SRTD-Biotech.html ; technical description https://srtd-biotech.com/technology/ ; scientific paper https://www.nature.com/articles/s41467-024-55547-6 .